Merck Sees Hyzaar As Counter To Bristol Antihypertensive Vanlev
Executive Summary
Merck's defense of its antihypertensive franchise following the launch of Bristol-Myers Squibb's Vanlev will include an emphasis on the efficacy of its angiotensin II/diuretic combination product Hyzaar.